The UK IBD Registry

UK IBD Registry

The national IBD audit is changing and the IBD Registry is now the vehicle for the biologics audit and quality improvement programme. Teams can participate using a choice of data entry systems including existing local systems.

Being part of the IBD Registry will give teams:

  • Local data to manage their biologics patients and IBD service more effectively
  • The chance to be part of a national audit of the safety and appropriate use of biologics and biosimilars

In time the Registry will become a unique resource for real-world clinical effectiveness and health economic studies in IBD care. The goals for 2016/17 are:

  • Transfer data collection to the IBD Registry from the RCP biological therapy audit web tool, which will be closing
  • Develop a near-complete UK Register of IBD patients on biologics by the end of 2017

Find out more about…

HOW TO JOIN DATA ENTRY OPTIONS

Making-Information-Work

Join our mailing list

Latest IBD Registry data submission and site numbers

As we approach the end of the year, the Registry team would like to thank all the IBD teams who have now joined the project for all their hard work. We’ve reached an important milestone in November with 20 sites

0 comments

Upload your patient data in November!

We are asking all sites that have any patient data live on a Registry-compatible system to upload their patient data to NHS Digital (HSCIC) during November. This is really important as the BSG Trustees will be assessing BSG support for

0 comments

2016 UK IBD Audit report highlights potential huge cost savings through the use of biosimilars

The report suggests that biosimilars are safe and effective for IBD patients and if adopted can reduce the cost of treatment by half. This is the final report produced by  the UK IBD audit at the Royal College of Physicians.

0 comments

Audit & Registry – where next?

The UK IBD Registry:
an introduction

Driving excellence with the IBD Registry

Dr Barney Hawthorne on IBD Registry as an opportunity for UK to be world-leading

Save

Save

Save

Save

Save

Save

Save

Save

Save

Save